Sellas doses first paediatric subject with AML in Phase II trial of SLS009
Sellas Life Sciences has dosed the first paediatric subject with acute myeloid leukaemia (AML) in its multi-centre Phase II trial…
All articles by
-
-
AviadoBio begins Phase I/II trial of FTD-GRN gene therapy in the UK
AviadoBio has opened the multi-centre Phase I/II ASPIRE-FTD trial in the UK, aimed at assessing the gene therapy candidate AVB-101…
-
Abbott’s studies show CGM technology linked to lower heart hospitalisation risk
Abbott's REFLECT real-world retrospective studies indicate that FreeStyle Libre continuous glucose monitoring (CGM) technology use is linked to a significant…
-
MSD’s Phase III trial of Keytruda meets endpoint for treating ovarian cancer
MSD has reported that the randomised Phase III KEYNOTE-B96 trial of Keytruda (pembrolizumab) plus chemotherapy (paclitaxel), with or without bevacizumab,…
-
First subject dosed in Revolution Medicines’ Phase III NSCLC treatment trial
Revolution Medicines has dosed the first subject in the Phase III RASolve 301 trial with the RAS (ON) multi-selective inhibitor,…
-
Pasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapy
Pasithea Therapeutics has announced the start of a Phase I/Ib open-label trial of macrocyclic mitogen-activated protein kinase (MEK) inhibitor, PAS-004,…
-
Nuvig Therapeutics begins dosing in trial of NVG-2089 for CIDP
Nuvig Therapeutics has dosed the first subject in its multi-centre Phase II INVGOR trial of recombinant human immunoglobulin G1-crystallisable fragment…
-
BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug
US-based biopharmaceutical company BridgeBio Pharma has dosed the first subject in the ACT-EARLY study of acoramidis, a drug intended to…
-
Roche reports final overall survival outcomes from breast cancer treatment trial
Swiss pharmaceutical company Roche has reported final overall survival outcomes from a long-term Phase III trial of Perjeta (pertuzumab) with…
-
Connect Biopharma begins Phase II trial of drug for acute exacerbations in asthma
US-based biopharmaceutical company Connect Biopharma has started a Phase II trial to assess the efficacy and safety of rademikibart in…
